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Abstract
Background: Metabolic syndrome (MetS) is defined as an accumulation of risk factors that include chronic
hypertension, dyslipidaemia, insulin resistance and obesity and leads to an increased risk for diabetes, cardiovascular
disease and stroke. MetS is widespread and estimated to affect up to a quarter of the global population. Patients
with MetS who undergo surgery are associated with an increased risk of postoperative complications when
compared with patients with a non-MetS profile. An emerging body of literature points to MetS being associated
with a greater risk of postoperative pulmonary complications (PPC) in the surgical patient. PPC are associated with
increased postoperative morbidity and mortality, Intensive care unit (ICU) admission, length of stay (ICU and
hospital), health care costs, resource usage, unplanned re-intubation and prolonged ventilatory time.
Methods/design: We will search for relevant studies in the following electronic bibliographic databases: EMBASE,
MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Scopus as well as scan the reference
lists of included studies for potential additional literature. Two authors will independently screen titles and abstracts to
identify potentially relevant studies for inclusion based on predefined inclusion and exclusion criteria. The Cochrane
Collaboration Review Manager (Review Manager 5) statistical software will be used to conduct this systematic review
and meta-analysis and generate forest plots to demonstrate comparison of findings across studies included for meta-
analysis. Subgroup and sensitivity analysis will be performed to assess the heterogeneity of included studies. A
descriptive synthesis of the statistical data will be provided to summarise the results and findings of the systematic
review and meta-analysis.
Discussion: This review will be the first to report and summarise the risk for and incidence of PPC in adult patients
with MetS undergoing surgery across a range of surgical specialities. The results have the potential to inform the
development of evidenced-based interventions to improve the management of PPC in the surgical patient with MetS.
Findings from this systematic review and meta-analysis will inform a subsequent Delphi study on priorities and
responses to PPC in patients with MetS. We will also disseminate our results through publication in scientific peer-
reviewed journals, conference presentations and promotion throughout our network of surgical safety champions in
clinical settings.
Systematic review registration: PROSPERO CRD42019120279.
Keywords: Metabolic syndrome, Surgery, Complications, Postoperative pulmonary complications, Systematic review,
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Background
Metabolic syndrome (MetS) is a global health problem
which leads to an increased risk of cardiovascular disease,
stroke, non-insulin dependent diabetes mellitus and prema-
ture death [1]. Individuals with MetS typically present with
symptoms that include elevated blood pressure, insulin
resistance, decreased high-density lipoproteins, elevated tri-
glycerides and obesity, particularly abdominal obesity [2, 3].
Typically, an individual is diagnosed with MetS when at least
three out of five of these components are present [4, 5].
However, these components vary slightly according to the
definition of MetS used. While the various definitions share
the same inherent risk factors, diagnostic criteria diverge
slightly across each definition. Historically, two commonly
used definitions are from the International Diabetes
Federation (IDF), and the National Cholesterol Education
Program Adult Treatment Panel III (NCEP:ATPIII) [6, 7].
To overcome the difficulties associated with multiple defini-
tions of MetS, leading health organisations produced a Joint
Interim Statement (JIS) to harmonise diagnostic criteria and
components of MetS into a unified, widely accepted, and
broadly adopted definition as outline in Table 1 [6].
Unifying and using a single diagnostic criteria for MetS is
important as previous global estimates of prevalence range
between 10% and 84% depending on region, age, ethnicity,
gender and race [1]. However, MetS is most commonly esti-
mated to be around 20 to 30% in adult populations within
developed economies [8, 9]. While an accurate prevalence of
MetS in surgical patients is not obtainable from the literature,
the prevalence of MetS in patients undergoing cardiac surgery
alone is estimated at approximately 46% [10, 11]. This esti-
mate is almost double that reported in the general population
[12, 13]. A diagnosis of MetS predicts the development of
chronic disease and deterioration of health. MetS increases
the risk for all-cause mortality 1.5 fold, stroke twofold, cardio-
vascular disease threefold, and type two diabetes mellitus
fivefold [1, 14–16]. MetS also predicts the development of a
range of chronic diseases including non-alcoholic steatohepa-
titis, neurological disorders and malignant neoplasms [17].
Having MetS is further associated with increased complica-
tions in patients undergoing surgery compared to patients
with a non-MetS profile. Frequently reported perioperative
adverse events indicate that patients with MetS are associated
with increased rates of postoperative morbidity compared to
patients without it specifically, infectious, cardiovascular and
renal postoperative adverse events [10, 18, 19].
One particular under-researched area of burden pre-
dicted by MetS relates to postoperative pulmonary compli-
cations (PPC) after surgery. PPC occur commonly and
increase patient mortality and morbidity as well as being
associated with increased health-care costs. One in five pa-
tients who develop a PPC will die within 30 days of major
surgery compared to 0.2–3% without [20] and an observa-
tional study has shown that there are long-term significant
differences in mortality rates at 1 and 5 years for patients
who have had a PPC [20]. Length of hospital stay is also
increased with resultant increased morbidity and this also
increases healthcare costs significantly [21]. Increasingly,
there are reports of a heightened risk of PPC among surgi-
cal patients’ with MetS. For example, in a study of 158,405
patients undergoing bariatric surgery, the complications of
atelectasis, pleural effusions, pneumonia, ARDS and re-
spiratory failure were associated with a significantly higher
percentage of occurrences in patients with MetS compared
to patients without a MetS diagnosis [22]. For patients
undergoing hepatic surgery, having MetS increases the risk
of unplanned re-intubation and prolonged ventilatory time
twofold [23]. In a study reporting on outcomes for patients
undergoing cardiac surgery, rates of PPC and length of ven-
tilatory time were significantly higher in patients with a
MetS profile [24]. In another retrospective cohort study of
310,280 patients undergoing non-cardiac surgery, the risk
for PPC was approximately 1.5 to threefold higher in pa-
tients when accompanied by a MetS diagnosis [25]. MetS
was found to be an independent positive predictor of PPC
in patients undergoing abdominal surgery [26]. Increased
rates of PPC were also reported in patients diagnosed with
MetS who underwent lumbar spinal fusion and shoulder
arthroplasty [27, 28]. An emerging body of literature
appears to associate MetS with a greater risk of PPC in the
surgical patient. However, no systematic review has been
performed to date meaning the risk of PPC in MetS pa-
tients is not well understood. Additionally, there are few
studies of interventions specifically targeting the needs of
the surgical patient with MetS. Our proposed systematic re-
view and meta-analysis will therefore be the first of its kind
to synthesise and critically appraise the current evidence
base. We will quantify the risk of PPC in patients with
metabolic syndrome versus those without metabolic syn-
drome in surgical populations.
Table 1 Diagnostic criteria for the metabolic syndrome
Measure Categorical cut–off points
Elevated waist circumference Population- and country-specific
definitions
Elevated triglycerides (drug
treatment for elevated triglycerides
is an alternate indicator)
≥ 150mg/dL (1.7 mmol/L)
Reduced HDL-C (drug treatment
for reduced HDL-C is an alternate
indicator)
< 40 mg/dL (1.0 mmol/L) in males;
< 50 mg/dL (1.3 mmol/L) in females
Elevated blood pressure
(antihypertensive drug treatment
in a patient with a history of
hypertension is an alternative
indicator
Systolic ≥ 130 and/or diastolic ≥
85 mmHg
Elevated fasting glucose (drug
treatment of elevated glucose in
an alternate indictor)
≥ 100mg/dL
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Objectives
The objective of this review is to evaluate the effect of
metabolic syndrome on the occurrence of PPC in adult sur-
gical patients versus those without metabolic syndrome.
Methods
Protocol
This systematic review will follow the Preferred Reporting
Items for Systematic Review and Meta-Analysis (PRISMA)
recommendations [29]. The systematic review protocol has
been registered in the International Prospective Register of
Systematic Reviews (PROSPERO CRD42019120279). A
PRISMA-P file is attached (see Additional file 1) [30].
Eligibility criteria
Criteria for considering studies
Study inclusion criteria This review will include peer-
reviewed literature that is published in electronic bibliographic
databases. Included studies must examine the relationship
between adult surgical patients 18 years of age and older diag-
nosed with MetS and the risk for and incidence of PPC in this
population. Studies will be restricted by design with only retro-
spective and prospective observational studies, cohort studies
and case-control studies being eligible for inclusion to obtain
a comprehensive overview of the existing evidence base.
Population
Surgical patients diagnosed with MetS versus surgical
patients without MetS.
Outcomes
The primary outcome will be the incidence of PPC in adult
surgical patients diagnosed with MetS at key surgical/clinical
time intervals. We will report outcomes of interest as odds ra-
tio, relative risk or incidence rate ratios. We will only record
outcomes reported within the first 30 days after surgery.
PPC will be defined using the European Perioperative
Clinical Outcomes (EPCO) definitions [31]. These include
respiratory infection, respiratory failure, pleural effusion,
atelectasis, pneumothorax, bronchospasm, aspiration pneu-
monitis, pneumonia, acute respiratory distress syndrome
(ARDS), tracheobronchitis, pulmonary oedema, exacerba-
tion of pre-existing lung disease and pulmonary embolism.
We will also record secondary outcomes of interest as
follows:
 Unplanned re-intubation within 30 days
 Prolonged ventilatory time > 72 h
Search strategy
We will conduct a comprehensive literature search of the
following electronic databases: MEDLINE (Medical Litera-
ture Analysis and Retrieval Online), CINAHL (Cumulative
Index to Nursing and Allied Health Literature), EMBASE
(ExerptaMedica Database) and Scopus to identify studies
pertinent to the review. A date restriction from January 1,
1998 until present, will be implemented to reflect the first
formal definition for metabolic syndrome which was de-
veloped in 1998 by the World Health Organization and
informed every subsequent definition of MetS since [6].
The types of studies that will be analysed and included
are retrospective or prospective observational studies,
cross-sectional studies, cohort studies and case control
studies. The types of studies that will be excluded are let-
ters, abstracts, conference papers and editorials. The initial
search terms reflect how metabolic syndrome is commonly
referred to in the literature. These keywords will include
the Medical Subject Heading for “metabolic syndrome” and
a range of synonyms used to represent surgery and post-
operative pulmonary complications. Search terms will be
limited to peer-reviewed full text-articles, in English lan-
guage with no geographical restriction (see Appendix 1).
To ensure that all relevant studies are included, a manual
search of citations and references of eligible studies will also be
conducted. Resulting references will be exported separately and
provided to two reviewers (PN and BV) for independent review.
Where necessary, study authors will be contacted for missing
information. To ensure impartiality the inclusion and exclusion
criteria will be engaged continuously (see Appendix 2).
Selection of studies
Following the search, studies selected for inclusion will be
collated into a citation management program (Endnote X8).
Duplicates will be removed and stored separately (Endnote
X8). Two reviewers (PN and BV) will independently screen
titles and abstracts for assessment against the inclusion cri-
teria and exclude all studies that do not meet these criteria.
Any disagreement will be resolved through discussion and
consensus. After the initial screening for studies, two re-
viewers (PN and BV) will retrieve the full text of selected
studies and assess against the inclusion criteria. Full-text
studies that meet the inclusion criteria will be imported into
Endnote X8. Full text studies that do not meet the inclusion
criteria will be excluded and reasons for exclusion will be
provided in an appendix in the final systematic review
report. Included studies will undergo a process of critical ap-
praisal. Any disagreements that arise between the reviewers
will be resolved through discussion, or with a third reviewer
(NR). The results of the search will be reported in the review
and presented in a PRISMA flow diagram, detailing the
steps taken in the full systematic review. The authors will be
contacted for missing data where required.
Data extraction and management
Two reviewers (PN and BV) will independently extract data
from the included studies into Cochrane Collaboration Re-
view Manager (Review Manager 5) to ensure consistency
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while reducing bias and improving validity and reliability
[32]. Any inconsistences between reviewers will be resolved
through consensus and a third reviewer will be consulted if
agreement cannot be reached. Study authors will be con-
tacted to obtain additional or missing data.
Extracted data will include the following:
1. Study details: title, journal, year, city and country
where the research was undertaken.
2. Participant demographics: sample size, group size
(e.g. metabolic syndrome group versus non-
metabolic syndrome group), reported complications,
metabolic syndrome diagnostic criteria applied, type
of surgery, population demographics.
3. Methods: study aim, data collection method, study
recruitment, design and sampling methods, study
eligibility as dictated by the inclusion criteria
4. Outcome measures: estimates of cumulative
incidence and incidence rate of PPC in adult
surgical patients diagnosed with MetS.
5. Limitations: study biases as identified by a risk of
bias tool for observational studies and limitations as
identified by the study authors.
Risk of bias
The methodological quality and bias of the included stud-
ies will be assessed using the Newcastle-Ottawa Quality
Assessment Scale (NOS) [33]. The NOS will evaluate non-
randomised studies included in systematic reviews and
meta-analyses across three quality parameters: study selec-
tion, comparability of the population and a determination
of whether the exposure or outcome includes risk of bias
[32]. NOS assesses the quality of each study and provides
a maximum score of nine points. Studies identified as hav-
ing a NOS greater than or equal to seven are considered
high quality. Studies between five and six points are con-
sidered as being of fair or moderate quality. Studies that
are assessed as having a NOS score of less than five points
represent a high risk of bias [32]. Two investigators (PN
and BV) will independently assess the risk of bias for in-
cluded studies using NOS quality criteria.
Data collection and analysis
We will conduct data analysis using the Cochrane Col-
laboration Review Manager (Review Manager 5) statis-
tical software to generate forest plots to demonstrate
comparison of findings across studies included for meta-
analysis. Meta-analysis will be performed if two or more
comparable studies are identified for each outcome of
interest. We anticipate clinical and methodological di-
versity as population and study characteristics will vary
across trials. The statistical heterogeneity of studies in-
cluded for meta-analysis will be assessed by calculating
the P value from the chi-squared test for homogeneity
and the I2 statistic. A P value of < 0.10 will be used to
determine statistical significance [28]. In the presence of
substantial heterogeneity (I2 is ≥ 50%), we will pool study-
specific estimates using a random effects model and
according to whether variables are dichotomous or con-
tinuous [34]. For dichotomous variables, individual study
data will be pooled and examined using the Mantel-
Haenszel to examine the overall association between the
exposure and outcome [35]. For continuous variables, we
will group measures using the inverse variance approach to
pool the standardised mean difference where studies have
employed different measures to calculate the outcome of
interest or weighted mean difference if studies report effi-
cacy in terms of a continuous outcome measurement [36].
If heterogeneity is low (I2 is ≤ 50%), pooled estimates will
be calculated using a fixed-effects model [36]. Measures of
relative effect will be expressed as odds ratio (OR) and 95%
confidence intervals (CIs) for dichotomous outcomes while
standard mean differences and 95% CIs will be calculated
for continuous outcomes. If statistical heterogeneity is
present, subgroup analysis (e.g. population according to the
MetS definition categories, surgery type, type of PPC, age
and gender) will be undertaken and meta-regression per-
formed to explore effect measure modification where the
modifiers are study level covariates. Sensitivity analysis will
be performed to identify study level categorical variables
that characterise the occurrence of the outcome of interest.
We will also assess the impact of outlier studies on the
pooled estimates of reported outcome measures among the
population of interest by performing outlier analysis.
If there are ten or more studies included in the meta-
analysis, the reviewers will assess for potential publica-
tion bias using funnel plots and Egger’s test [37]. Any
discrepancies of quality assessment between the two re-
viewers (PN and BV) will be resolved through discussion
and consensus or by a third reviewer (NR).
Discussion
To our knowledge, this systematic review and meta-
analysis will be the first to evaluate the risk of PPC follow-
ing surgery in patients with and without MetS. If MetS in-
creases the probability of complications following surgery,
patients should be made aware of these risks while clini-
cians should develop interventions to reduce or eliminate
the likelihood of PPC occurring. Following our review, we
will use numerous strategies to disseminate our findings.
Examples include conference presentations, media re-
leases, meetings with healthcare leaders and expansion of
our current research program in metabolic syndrome [16]
to include PPC intervention development. We will also
use findings from our review to inform a subsequent
Delphi study as described in [38] to identify expert con-
sensus on priorities for improving outcomes among surgi-
cal patients with metabolic syndrome.
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Appendix 1
Table 2 Example search strategies
Search Date MEDLINE search strategy
January 06, 2019 ((“surgical procedures, operative”[MeSH Major Topic] OR “surgery”[Title/Abstract]) AND
(“metabolic syndrome”[MeSH Major Topic] OR “metabolic syndrome”[Title/Abstract])) AND
(((“lung”[MeSH Major Topic] OR “respiratory therapy”[MeSH Major Topic]) OR “lung”[Title/Abstract])
OR “pulmonary”[Title/Abstract])AND (“1998/01/01”[PDAT]: “2019/01/18”[PDAT]) AND
(“1998/01/01”[PDAT]: “2019/01/18”[PDAT])
Search Date CINAHL search strategy
January 06, 2019 (((TI Metabolic syndrome) OR (AB metabolic syndrome)) AND (((TI surgical procedures) OR
(AB surgical procedures) OR ((TI operative) OR (AB operative)) OR ((TI surgery) OR (AB surgery)
AND (((TI Metabolic syndrome) OR (AB metabolic syndrome)) AND (((TI respiratory therapy) OR
(AB respiratory therapy)) OR ((TI lungs) OR (AB lungs)) OR ((pulmonary) OR (AB pulmonary))) with
limiters of a published date from 1998/01/01
Search Date ScienceDirect search strategy
January 06, 2019 title-abs-key (metabolic syndrome) AND title-abs-key (surgical procedures*) OR title-abs-key
(operative*) OR title-abs-key (surgery*) AND title-abs-key (respiratory therapy*) OR title-abs-key
(lung) OR title-abs-key (pulmonary) AND LIMIT-TO (yearnav, “2019, 2018, 2017, 2016, 2015, 2014,
2013, 2012, 2011, 2010, 2009, 2008, 2007, 2006, 2005, 2004, 2003, 2002, 2001, 2000, 1999, 1998”)
AND LIMIT-TO (contenttype, “JL, BS”, “Journal”).
Search Date Embase Search strategy
January 06, 2019 ‘metabolic syndrome’:ab,ti AND surgical procedures: ab,ti OR operative: ab,ti OR surgery ab,ti AND
pulmonary:ab,ti OR respiratory therapy:ab,ti OR lungs ab.ti[1998–2019]/py AND [english]/lim
AND [humans]/lim
Appendix 2
Table 3 Example inclusion and exclusion criteria
Example inclusion criteria Example exclusion criteria
Study population
• Adult patients (18 years or older)
• Adult patients with a diagnosis of metabolic syndrome as per author definition
• Adult patients undergoing moderate or highly invasive surgery of all types
Study surgical procedure
• Adult patients undergoing moderate or highly invasive surgery of all types
Study design
• Observational studies (e.g. cohort studies, case-control studies)
• Published peer-reviewed articles in the English language
Study population
• Surgical patients < 18 years of age
• Animals
• Pregnant women
Study surgical procedure
• Minor procedures
• Caesarean section
• Trauma surgery
• Day surgical procedures
• Cataract procedures
• Plastic surgery
• Cosmetic surgery
• Cardiac catheterisation
• Cystoscopy procedures
• Endoscopy procedures
• Colonoscopy procedures
• Lesion removal
Study design
• Interventional studies
• Conference procedures
• Narrative reviews
• Editorials
• Lectures and presentations
• Articles in a language other than English
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